No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors - 18/04/17

Doi : 10.1016/j.jinf.2017.01.007

Petra J. Woestenberg ^a,^b,^⁎ , Audrey J. King ^a , Marianne A.B. van der Sande ^a,^c , Robine Donken ^a,^d , Suzan Leussink ^a , Fiona R.M. van der Klis ^a , Christian J.P.A. Hoebe ^b,^e , Johannes A. Bogaards ^a , Birgit H.B. van Benthem ^a
on behalf of the
Medical Microbiological Laboratories
D. Adema ^g, R. Buist-Arkema ^g, A. Beerens ^g, D. Luijt ^g, S. Meijer ^g, J. Schirm ^g, A. Buiting ^h, M. Peeters ^h, J. Rossen ^h, H. Verbakel ^h, P. van Esch ^h, J. Verweij ^h, A. van der Eijk ⁱ, R. Huisman ⁱ, C. Kerkhof ⁱ, H. Korff ⁱ, M. Schutten ⁱ, J. Velzing ⁱ, F. Verduyn-Lunel ^j, S. Lakbiach ^j, P. van Rosmalen ^j, R. Schuurman ^j, D. Abma ^k, K. Adams ^k, S. Bruisten ^k, I. Linde ^k, P. Oostvogel ^k, C. Touwen ^k, W. Vermeulen ^k, A. Brink ^l, J. Nelissen ^l, P. Wolffs ^l, N. Duijvendijk ^m, P. Schneeberger ^m, M. Dinnissen-van Poppel ⁿ, W. Melchers ⁿ, Y. Poort ⁿ, M. Hooghiemstra ^o, H. Huisman ^o, J. Weel ^o, H. Bosch ^p, T. de Haas ^p, R. Kleinspenkelink ^p, I. Polman ^p, T. Smits ^p, P. van Goor ^q, M. Wolfhagen ^q, C. de Mooij ^r, E. van Koolwijk ^r, M. Peters ^r, C. Swanink ^r, R. Tiemessen ^r, T. van Zwet ^r, J. Janssen ^s, M. Pelsers ^s, W. de Waal ^t
^g Certe, The Netherlands
^h ETZ Hospital Tilburg, The Netherlands
ⁱ Erasmus Medical Center, The Netherlands
^j University Medical Center Utrecht, The Netherlands
^k Public Health Laboratory Amsterdam, The Netherlands
^l Maastricht University Medical Center, The Netherlands
^m Jeroen Bosch Hospital, The Netherlands
ⁿ Radboud University Medical Center, The Netherlands
^o Izore, The Netherlands
^p LabMicTA, The Netherlands
^q Isala, The Netherlands
^r Rijnstate, The Netherlands
^s Medical Laboratory Dr. Stein & College, The Netherlands
^t Canisius Wilhelmina Hospital, The Netherlands

and the
Public Health Services^{^f}
Membership of the Medical Microbiological Laboratories and Public Health Services is provided in the Acknowledgments.
G. Aalfs ^u, J. Kiewiet ^u, P. Sanders ^u, H. van Buel-Bruins ^v, C. van Bokhoven-Rombouts ^w, P. Cornelissen ^w, M. Kersten ^w, C. van Ruitenbeek ^w, I. Molenaar ^w, E. Doorn ^x, L. Masthoff ^x, E. Pannekoek ^x, V. Sigurdsson ^x, H. Götz ^y, M. Illidge-Onder de Linden ^y, M. Mattijssen ^y, J. Stam ^y, E. Swaders ^y, F. de Groot ^z, F. Postma ^z, E. Brouwers ^aa, A. Niekamp ^aa, M. Smit ^aa, A. Botraby ^ab, D. Bukasa ^ab, C. de Haan ^ab, P. Hut-van Vliet ^ab, T. Taconis ^ab, M. de Graas ^ac, I. Hondelink ^ac, C. Kampman ^ac, A. Gelissen-Hansen ^ad, I. de Koning ^ad, H. van Kruchten ^ad, M. van de Pas ^ad, H. Fennema ^ae,^{^{ag
Deceased.}}, T. Heijman ^ae, A. Hogewoning ^ae, A. van Leeuwen ^ae, M. van Rooijen ^ae, F. Neienhuijsen ^af, M. Pelgrim ^af
^u PHS Drenthe, Germany
^v PHS IJsselland, The Netherlands
^w PHS Gelderland-Zuid, The Netherlands
^x University Medical Center Utrecht, The Netherlands
^y PHS Rotterdam-Rijnmond, The Netherlands
^z PHS Groningen, The Netherlands
^aa PHS Zuid Limburg, The Netherlands
^ab PHS Fryslân, The Netherlands
^ac PHS Twente, The Netherlands
^ad PHS Hart voor Brabant, The Netherlands
^ae PHS Amsterdam, The Netherlands
^af PHS Gelderland-Midden, The Netherlands

^a Center for Infectious Disease Control, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands
^b School of Public Health and Primary Care, Maastricht University Medical Center, P.O. Box 616, 6200 MD Maastricht, The Netherlands
^c Julius Center, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
^d Department of Pathology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
^e Department of Sexual Health, Infectious Diseases and Environment, South Limburg Public Health Service, P.O. Box 2022, 6160 HA Geleen, The Netherlands

^∗Corresponding author. National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb), Postbox 1 (internal postbox 75), 3720 BA Bilthoven, The Netherlands. Fax: +31 30 274 44 09.National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control (CIb)Postbox 1 (internal postbox 75)Bilthoven3720 BAThe Netherlands

Summary

Objectives

Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.

Methods

We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.

Results

Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74–1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22–2.07) for women vaccinated at least once. Adjustment did not change these results.

Conclusions

We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.

Le texte complet de cet article est disponible en PDF.

Keywords : Human papillomavirus 6, Human papillomavirus 11, Condylomata acuminata, Warts, Vaccination, Human papillomavirus vaccine, L1 type 16, 18, Prevention & control

Plan

Introduction

Materials and methods

Study design and population

Conflicts of interest

Export

Vol 74 - N° 4

P. 393-400 - avril 2017 Retour au numéro

Article précédent

Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection
Lauri Ivaska, Jussi Niemelä, Johanna Lempainen, Riikka Österback, Matti Waris, Tytti Vuorinen, Jukka Hytönen, Kaisu Rantakokko-Jalava, Ville Peltola

| Article suivant

Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study
Joseph M. Lewis, Colette Smith, Adele Torkington, Craig Davies, Shazaad Ahmad, Andrew Tomkins, Jonathan Shaw, Margaret Kingston, Ghadeer Muqbill, Philip Hay, Larissa Mulka, Deborah Williams, Laura Waters, Nataliya Brima, Neal Marshall, Margaret Johnson, Mas Chaponda, Mark Nelson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors - 18/04/17

Summary

Objectives

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL